Analyze Diet
Journal of veterinary internal medicine2023; doi: 10.1111/jvim.16818

Utility of serum amyloid A in monitoring clinical response to antimicrobial treatment in horses with bacterial pneumonia.

Abstract: Serum amyloid A (SAA) is a major acute phase protein in horses which could be a useful tool for assessing clinical response to treatment of bacterial pneumonia in adult horses.
Publication Date: 2023-07-31 PubMed ID: 37522636DOI: 10.1111/jvim.16818Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study is about the utility of measuring Serum amyloid A (SAA) concentrations in horses with bacterial pneumonia.

Background:

  • Serum amyloid A (SAA): This is a major acute phase protein in horses. An acute phase protein is a type of protein whose plasma concentration increases (or decreases) in response to inflammation.
  • Purpose of the Study: The researchers wanted to explore if SAA could be helpful in tracking how well adult horses with bacterial pneumonia respond to treatment.

Objectives:

  • The study aimed to:
    1. Track the SAA levels in horses as they underwent treatment for bacterial pneumonia.
    2. Check if there’s a relationship between SAA levels and other indicators like White Blood Cell (WBC) count, neutrophil count (a type of white blood cell), and fibrinogen (a protein involved in clotting).

Animals:

  • The study involved 18 adult horses diagnosed with bacterial pneumonia.

Methods:

  • This was a prospective clinical study, meaning they started measuring after the horses were diagnosed.
  • After being hospitalized, each horse’s SAA levels and vital signs were checked daily using a handheld meter.
  • Blood tests to measure Complete Blood Count (CBC) and plasma fibrinogen were done initially and then at specified intervals.
  • Since the data wasn’t distributed normally, they used a mathematical approach (log transformation) to make it suitable for statistical analysis.

Results:

  • The average SAA level at the start was 537 μg/mL.
  • The SAA levels went up, peaking on day 2, and then decreased gradually as the horses were treated.
  • This drop in SAA over time was statistically significant.
  • However, other measurements like fibrinogen, neutrophil count, and WBC count didn’t show any significant change throughout the treatment.

Conclusions:

  • The SAA concentration in the horses decreased notably as they underwent treatment for pneumonia. This drop in SAA was in line with the clinical improvement seen in the horses.
  • In contrast, other parameters like fibrinogen, neutrophil, and WBC counts didn’t show consistent trends.

In simpler terms: The study found that tracking the levels of SAA in horses with bacterial pneumonia could be a useful way to see how well they’re responding to treatment. This is especially helpful since other common measures didn’t show consistent results.

Cite This Article

APA
Hepworth-Warren KL, Estell K, Cowles B, Amodie D, Crisman M. (2023). Utility of serum amyloid A in monitoring clinical response to antimicrobial treatment in horses with bacterial pneumonia. J Vet Intern Med. https://doi.org/10.1111/jvim.16818

Publication

ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English

Researcher Affiliations

Hepworth-Warren, Kate L
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Estell, Krista
  • Virginia Tech's Marion duPont Scott Equine Medical Center, Leesburg, Virginia, USA.
Cowles, Bobby
  • Zoetis, Parsippany, New Jersey, USA.
Amodie, Deborah
  • Zoetis, Parsippany, New Jersey, USA.
Crisman, Mark
  • Zoetis, Parsippany, New Jersey, USA.

References

This article includes 17 references
  1. Wallace K. Proteins. In: Walton RM, ed. Equine Clinical Pathology. 1st ed. Ames, IA: Wiley-Blackwell; 2014:119-130.
  2. Viner M, Mazan M, Bedenice D, Mapes S, Pusterla N. Comparison of serum amyloid a in horses with infectious and noninfectious respiratory diseases. J Equine Vet Sci 2017;49:11-13.
  3. Cohen ND, Chaffin MK, Vandenplas ML. Study of serum amyloid a concentrations as a means of achieving early diagnosis of Rhodococcus Equi pneumonia. Equine Vet J 2005;37:212-216.
  4. Giguère S, Berghaus LJ, Miller CD. Clinical assessment of a point-of-care serum amyloid a assay in foals with bronchopneumonia. J Vet Intern Med 2016;30:1338-1343.
  5. Hobo S, Niwa H, Anzai T. Evaluation of serum amyloid a and surfactant protein D in sera for identification of the clinical condition of horses with bacterial pneumonia. J Vet Med Sci 2007;69:827-830.
  6. Ferrucci F, Zucca E, Croci C, di Fabio V, Martino PA, Ferro E. Bacterial pneumonia and pleuropneumonia in sport horses: 17 cases (2001-2003). Equine Vet Educ 2008;20:526-531.
  7. Reuss SM, Giguère S. Update on bacterial pneumonia and pleuropneumonia in the adult horse. Vet Clin North Am Equine 2015;31:105-120.
  8. Arroyo MG, Slovis NM, Moore GE, Taylor SD. Factors associated with survival in 97 horses with septic pleuropneumonia. J Vet Intern Med 2017;31:894-900.
  9. Estell KE, Young A, Kozikowski T. Pneumonia caused by Klebsiella Spp. in 46 horses. J Vet Intern Med 2016;30:314-321.
  10. Schwartz D, Pusterla N, Jacobsen S, Christopher MM. Analytical validation of a new point-of-care assay for serum amyloid a in horses. Equine Vet J 2018;50:678-683.
  11. McKenzie HC. Diagnosis and Management of Bacterial Pneumonia in adult horses. AAEP Proc 2011;57:8-11.
  12. Rodrigues NF, Giraud L, Bolen G. Comparison of lung ultrasound, chest radiographs, C-reactive protein, and clinical findings in dogs treated for aspiration pneumonia. J Vet Intern Med 2022;36:743-752.
  13. Viitanen SJ, Lappalainen AK, Christensen MB, Sankari S, Rajamaki MM. The utility of acute-phase proteins in the assessment of treatment response in dogs with bacterial pneumonia. J Vet Intern Med 2017;31:124-133.
  14. Menard J, Porter I, Lerer A, Robbins S, Johnson PJ, Goggs R. Serial evaluation of thoracic radiographs and acute phase proteins in dogs with pneumonia. J Vet Intern Med 2022;36:1430-1443.
  15. Pink I, Raupach D, Fuge J. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection 2021;49:935-943.
  16. Christ-Crain M, Stolz D, Bingisser R. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93.
  17. Metlay JP, Waterer GW, Long AC. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45-e67.

Citations

This article has been cited 3 times.
  1. Zhang X, Zhou D, Chu J. Expression and clinical significance of IL-17 and its receptor in bacterial pneumonia before and after treatment. Am J Transl Res 2025;17(12):9715-9726.
    doi: 10.62347/AHPX9239pubmed: 41552330google scholar: lookup
  2. Hepworth-Warren KL, Love K. Survey of the approach to the diagnosis and management of bacterial pneumonia in adult horses by equine veterinarians. Front Vet Sci 2024;11:1484970.
    doi: 10.3389/fvets.2024.1484970pubmed: 39764370google scholar: lookup
  3. Hallowell KL, Hepworth-Warren KL, Dembek K. An updated description of bacterial pneumonia in adult horses and factors associated with death. J Vet Intern Med 2024 Sep-Oct;38(5):2766-2775.
    doi: 10.1111/jvim.17141pubmed: 39005215google scholar: lookup